Transmembrane Channel-Like 6 (TMC6) (1st lumenal part) Antikörper

Antigen: Transmembrane Channel-Like 6 (TMC6)

Synonyme: EV1, EVER1, EVIN1, LAK-4P, FLJ17776, D11Ertd204e, MGC139990, MGC83549, ever1

Epitope: 1st lumenal part

Klonalität: Polyklonal

Wirt: Kaninchen

Reaktivität: Human

Applikation: Immunhistochemie (IHC), Western Blot (WB)

Produktnummer: ABIN351052

Produktbeschreibung

Weitere Bezeichnung: transmembrane channel-like protein 6 (TMC6, EVER1, Protein LAK-4, EVIN1) (1t lumenal part)

Swiss-Prot: Q7Z403

Immunogen: A synthetic peptide from the 1t lumenal part of human transmembrane channel-like protein 6 (TMC6, EVER1, Protein LAK-4, EVIN1) conjugated to an immunogenic carrier protein was used as the immunogen.

Format: Lyophilized

Beschreibung: SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass membrane protein. TISSUE SPECIFICITY: Expressed in placenta, prostate, testis, activated T-lymphocytes and lymphokine-activated killer (LAK) lymphocytes. DISEASE: Defects in TMC6 are a cause of epidermodysplasia verruciformis. It is a rare autosomal recessive genodermatosis associated with a high risk of skin carcinoma that results from an abnormal susceptibility to infection by specific human papillomaviruses. Infection leads to persistent wart-like or macular lesions. Also known as: TMC6, EVER1, Epidermodysplasia verruciformis protein 1, Protein LAK-4, EVIN1.

Spezifität: Appears to be specific for TMC6.

Anwendungen

Applikationshinweise: IHC, WB. A dilution of 1 : 300 to 1 : 4000 is recommended. The optimal dilution should be determined by the end user.

Reinheit: whole serum

Lagerung: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Ramoz, Rueda, Bouadjar et al.: "Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis." in: Nature genetics, Vol. 32, Issue 4, pp. 579-81, 2002 (PubMed).

Kurima, Yang, Sorber et al.: "Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis." in: Genomics, Vol. 82, Issue 3, pp. 300-8, 2003 (PubMed).

Ota, Suzuki, Nishikawa et al.: "Complete sequencing and characterization of 21,243 full-length human cDNAs." in: Nature genetics, Vol. 36, Issue 1, pp. 40-5, 2003 (PubMed).

Tate, Suzuki, Kishimoto et al.: "Novel mutations of EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis." in: Journal of human genetics, Vol. 49, Issue 4, pp. 223-5, 2004 (PubMed).

Olsen, Blagoev, Gnad et al.: "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." in: Cell, Vol. 127, Issue 3, pp. 635-48, 2006 (PubMed).